Evidence map›Paper›PMID 24888818›Full record

Trial reportJournal of clinical oncology : official journal of the American Society of Clinical Oncology2014

Circulating tumor cells and response to chemotherapy in metastatic breast cancer: SWOG S0500.

Jeffrey B Smerage, William E Barlow, Gabriel N Hortobagyi, Eric P Winer, Brian Leyland-Jones, Gordan Srkalovic, Sheela Tejwani, Anne F Schott, Mark A O'Rourke, Danika L Lew and 4 more

3 registry-linked trialsAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 323 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
323citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02505139 completednot on this map

Using Circulating Tumor Cells to Diagnose and Predict Prognosis in Metastatic Nasopharyngeal Carcinoma Patients

TypeobservationalSponsorSun Yat-sen UniversityRan2014 to 2016Enrolled166ConditionsNasopharyngeal NeoplasmsArmsthe number of circulating tumor cells
NCT03979339 naunknown statusnot on this mapstarted 2020, after this paper: background citation

Feasibility of a New Technology for Isolating Circulating Tumour Cells in Selected Cancer Patients and Healthy Volunteers

TypeinterventionalSponsorCentre Oscar LambretRan2020 to 2023Enrolled76ConditionsHER2-positive Metastatic Breast Cancer, Ovarian Cancer, Hormone-resistant Prostate Cancer, Circulating Tumor CellArmsBlood sample collection
NCT06717295 recruitingnot on this mapstarted 2025, after this paper: background citation

The CCANED-CIPHER Study: Early Cancer Detection and Treatment Response Monitoring Using AI-Based Platelet and Immune Cell Transcriptomic Profiling

TypeobservationalSponsorJavier ToledoRan2025 to 2028Enrolled6,000ConditionsBrest Cancer, Lung Cancer (NSCLC), Pancreatic Cancer, Adult, Prostate CancersArmsDiNanoQ: A multi-cancer early detection (MCED) blood test, DiNanoTrack: Therapeutic Response Monitoring Blood Test
3 · Its place in the literature

Who cites it

323 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Utility of Liquid Biopsy Analysis in Detection of Hepatocellular Carcinoma, Determination of Prognosis, and Disease Monitoring: A Systematic Review.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2020
    Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Review
  14. Review
  15. Review
  16. Review
  17. Article
  18. Article
  19. Article
  20. Review

263 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors.

Jeffrey B SmerageJeffrey B. Smerage, Anne F. Schott, and Daniel F. Hayes, University of Michigan Comprehensive Cancer Center, Ann Arbor; Gordan Srkalovic, Sparrow Regional Cancer Center, Lansing; Sheela Tejwani, Henry Ford Hospital, Detroit, MI; William E. Barlow and Danika L. Lew, SWOG Statistical Center; Julie R. Gralow, Seattle Cancer Care Alliance, Seattle, WA; Gabriel N. Hortobagyi, University of Texas MD Anderson Cancer Center, Houston, TX; Eric P. Winer, Dana-Farber Cancer Institute, Boston, MA; Brian Leyland-Jones, Avera Cancer Institute, Sioux Falls, SD; Mark A. O'Rourke, Greenville Health System Cancer Institute/Greenville Community Clinical Oncology Program, Greenville, SC; Gerald V. Doyle, Immunicon, Huntingdon Valley, PA; and Robert B. Livingston, University of Arizona Cancer Center, Tucson, AZ.
William E BarlowJeffrey B. Smerage, Anne F. Schott, and Daniel F. Hayes, University of Michigan Comprehensive Cancer Center, Ann Arbor; Gordan Srkalovic, Sparrow Regional Cancer Center, Lansing; Sheela Tejwani, Henry Ford Hospital, Detroit, MI; William E. Barlow and Danika L. Lew, SWOG Statistical Center; Julie R. Gralow, Seattle Cancer Care Alliance, Seattle, WA; Gabriel N. Hortobagyi, University of Texas MD Anderson Cancer Center, Houston, TX; Eric P. Winer, Dana-Farber Cancer Institute, Boston, MA; Brian Leyland-Jones, Avera Cancer Institute, Sioux Falls, SD; Mark A. O'Rourke, Greenville Health System Cancer Institute/Greenville Community Clinical Oncology Program, Greenville, SC; Gerald V. Doyle, Immunicon, Huntingdon Valley, PA; and Robert B. Livingston, University of Arizona Cancer Center, Tucson, AZ.
Gabriel N HortobagyiJeffrey B. Smerage, Anne F. Schott, and Daniel F. Hayes, University of Michigan Comprehensive Cancer Center, Ann Arbor; Gordan Srkalovic, Sparrow Regional Cancer Center, Lansing; Sheela Tejwani, Henry Ford Hospital, Detroit, MI; William E. Barlow and Danika L. Lew, SWOG Statistical Center; Julie R. Gralow, Seattle Cancer Care Alliance, Seattle, WA; Gabriel N. Hortobagyi, University of Texas MD Anderson Cancer Center, Houston, TX; Eric P. Winer, Dana-Farber Cancer Institute, Boston, MA; Brian Leyland-Jones, Avera Cancer Institute, Sioux Falls, SD; Mark A. O'Rourke, Greenville Health System Cancer Institute/Greenville Community Clinical Oncology Program, Greenville, SC; Gerald V. Doyle, Immunicon, Huntingdon Valley, PA; and Robert B. Livingston, University of Arizona Cancer Center, Tucson, AZ.
Eric P WinerJeffrey B. Smerage, Anne F. Schott, and Daniel F. Hayes, University of Michigan Comprehensive Cancer Center, Ann Arbor; Gordan Srkalovic, Sparrow Regional Cancer Center, Lansing; Sheela Tejwani, Henry Ford Hospital, Detroit, MI; William E. Barlow and Danika L. Lew, SWOG Statistical Center; Julie R. Gralow, Seattle Cancer Care Alliance, Seattle, WA; Gabriel N. Hortobagyi, University of Texas MD Anderson Cancer Center, Houston, TX; Eric P. Winer, Dana-Farber Cancer Institute, Boston, MA; Brian Leyland-Jones, Avera Cancer Institute, Sioux Falls, SD; Mark A. O'Rourke, Greenville Health System Cancer Institute/Greenville Community Clinical Oncology Program, Greenville, SC; Gerald V. Doyle, Immunicon, Huntingdon Valley, PA; and Robert B. Livingston, University of Arizona Cancer Center, Tucson, AZ.
Brian Leyland-JonesJeffrey B. Smerage, Anne F. Schott, and Daniel F. Hayes, University of Michigan Comprehensive Cancer Center, Ann Arbor; Gordan Srkalovic, Sparrow Regional Cancer Center, Lansing; Sheela Tejwani, Henry Ford Hospital, Detroit, MI; William E. Barlow and Danika L. Lew, SWOG Statistical Center; Julie R. Gralow, Seattle Cancer Care Alliance, Seattle, WA; Gabriel N. Hortobagyi, University of Texas MD Anderson Cancer Center, Houston, TX; Eric P. Winer, Dana-Farber Cancer Institute, Boston, MA; Brian Leyland-Jones, Avera Cancer Institute, Sioux Falls, SD; Mark A. O'Rourke, Greenville Health System Cancer Institute/Greenville Community Clinical Oncology Program, Greenville, SC; Gerald V. Doyle, Immunicon, Huntingdon Valley, PA; and Robert B. Livingston, University of Arizona Cancer Center, Tucson, AZ.
Gordan SrkalovicJeffrey B. Smerage, Anne F. Schott, and Daniel F. Hayes, University of Michigan Comprehensive Cancer Center, Ann Arbor; Gordan Srkalovic, Sparrow Regional Cancer Center, Lansing; Sheela Tejwani, Henry Ford Hospital, Detroit, MI; William E. Barlow and Danika L. Lew, SWOG Statistical Center; Julie R. Gralow, Seattle Cancer Care Alliance, Seattle, WA; Gabriel N. Hortobagyi, University of Texas MD Anderson Cancer Center, Houston, TX; Eric P. Winer, Dana-Farber Cancer Institute, Boston, MA; Brian Leyland-Jones, Avera Cancer Institute, Sioux Falls, SD; Mark A. O'Rourke, Greenville Health System Cancer Institute/Greenville Community Clinical Oncology Program, Greenville, SC; Gerald V. Doyle, Immunicon, Huntingdon Valley, PA; and Robert B. Livingston, University of Arizona Cancer Center, Tucson, AZ.
Sheela TejwaniJeffrey B. Smerage, Anne F. Schott, and Daniel F. Hayes, University of Michigan Comprehensive Cancer Center, Ann Arbor; Gordan Srkalovic, Sparrow Regional Cancer Center, Lansing; Sheela Tejwani, Henry Ford Hospital, Detroit, MI; William E. Barlow and Danika L. Lew, SWOG Statistical Center; Julie R. Gralow, Seattle Cancer Care Alliance, Seattle, WA; Gabriel N. Hortobagyi, University of Texas MD Anderson Cancer Center, Houston, TX; Eric P. Winer, Dana-Farber Cancer Institute, Boston, MA; Brian Leyland-Jones, Avera Cancer Institute, Sioux Falls, SD; Mark A. O'Rourke, Greenville Health System Cancer Institute/Greenville Community Clinical Oncology Program, Greenville, SC; Gerald V. Doyle, Immunicon, Huntingdon Valley, PA; and Robert B. Livingston, University of Arizona Cancer Center, Tucson, AZ.
Anne F SchottJeffrey B. Smerage, Anne F. Schott, and Daniel F. Hayes, University of Michigan Comprehensive Cancer Center, Ann Arbor; Gordan Srkalovic, Sparrow Regional Cancer Center, Lansing; Sheela Tejwani, Henry Ford Hospital, Detroit, MI; William E. Barlow and Danika L. Lew, SWOG Statistical Center; Julie R. Gralow, Seattle Cancer Care Alliance, Seattle, WA; Gabriel N. Hortobagyi, University of Texas MD Anderson Cancer Center, Houston, TX; Eric P. Winer, Dana-Farber Cancer Institute, Boston, MA; Brian Leyland-Jones, Avera Cancer Institute, Sioux Falls, SD; Mark A. O'Rourke, Greenville Health System Cancer Institute/Greenville Community Clinical Oncology Program, Greenville, SC; Gerald V. Doyle, Immunicon, Huntingdon Valley, PA; and Robert B. Livingston, University of Arizona Cancer Center, Tucson, AZ.
Mark A O'RourkeJeffrey B. Smerage, Anne F. Schott, and Daniel F. Hayes, University of Michigan Comprehensive Cancer Center, Ann Arbor; Gordan Srkalovic, Sparrow Regional Cancer Center, Lansing; Sheela Tejwani, Henry Ford Hospital, Detroit, MI; William E. Barlow and Danika L. Lew, SWOG Statistical Center; Julie R. Gralow, Seattle Cancer Care Alliance, Seattle, WA; Gabriel N. Hortobagyi, University of Texas MD Anderson Cancer Center, Houston, TX; Eric P. Winer, Dana-Farber Cancer Institute, Boston, MA; Brian Leyland-Jones, Avera Cancer Institute, Sioux Falls, SD; Mark A. O'Rourke, Greenville Health System Cancer Institute/Greenville Community Clinical Oncology Program, Greenville, SC; Gerald V. Doyle, Immunicon, Huntingdon Valley, PA; and Robert B. Livingston, University of Arizona Cancer Center, Tucson, AZ.
Danika L LewJeffrey B. Smerage, Anne F. Schott, and Daniel F. Hayes, University of Michigan Comprehensive Cancer Center, Ann Arbor; Gordan Srkalovic, Sparrow Regional Cancer Center, Lansing; Sheela Tejwani, Henry Ford Hospital, Detroit, MI; William E. Barlow and Danika L. Lew, SWOG Statistical Center; Julie R. Gralow, Seattle Cancer Care Alliance, Seattle, WA; Gabriel N. Hortobagyi, University of Texas MD Anderson Cancer Center, Houston, TX; Eric P. Winer, Dana-Farber Cancer Institute, Boston, MA; Brian Leyland-Jones, Avera Cancer Institute, Sioux Falls, SD; Mark A. O'Rourke, Greenville Health System Cancer Institute/Greenville Community Clinical Oncology Program, Greenville, SC; Gerald V. Doyle, Immunicon, Huntingdon Valley, PA; and Robert B. Livingston, University of Arizona Cancer Center, Tucson, AZ.
Gerald V DoyleJeffrey B. Smerage, Anne F. Schott, and Daniel F. Hayes, University of Michigan Comprehensive Cancer Center, Ann Arbor; Gordan Srkalovic, Sparrow Regional Cancer Center, Lansing; Sheela Tejwani, Henry Ford Hospital, Detroit, MI; William E. Barlow and Danika L. Lew, SWOG Statistical Center; Julie R. Gralow, Seattle Cancer Care Alliance, Seattle, WA; Gabriel N. Hortobagyi, University of Texas MD Anderson Cancer Center, Houston, TX; Eric P. Winer, Dana-Farber Cancer Institute, Boston, MA; Brian Leyland-Jones, Avera Cancer Institute, Sioux Falls, SD; Mark A. O'Rourke, Greenville Health System Cancer Institute/Greenville Community Clinical Oncology Program, Greenville, SC; Gerald V. Doyle, Immunicon, Huntingdon Valley, PA; and Robert B. Livingston, University of Arizona Cancer Center, Tucson, AZ.
Julie R GralowJeffrey B. Smerage, Anne F. Schott, and Daniel F. Hayes, University of Michigan Comprehensive Cancer Center, Ann Arbor; Gordan Srkalovic, Sparrow Regional Cancer Center, Lansing; Sheela Tejwani, Henry Ford Hospital, Detroit, MI; William E. Barlow and Danika L. Lew, SWOG Statistical Center; Julie R. Gralow, Seattle Cancer Care Alliance, Seattle, WA; Gabriel N. Hortobagyi, University of Texas MD Anderson Cancer Center, Houston, TX; Eric P. Winer, Dana-Farber Cancer Institute, Boston, MA; Brian Leyland-Jones, Avera Cancer Institute, Sioux Falls, SD; Mark A. O'Rourke, Greenville Health System Cancer Institute/Greenville Community Clinical Oncology Program, Greenville, SC; Gerald V. Doyle, Immunicon, Huntingdon Valley, PA; and Robert B. Livingston, University of Arizona Cancer Center, Tucson, AZ.
Robert B LivingstonJeffrey B. Smerage, Anne F. Schott, and Daniel F. Hayes, University of Michigan Comprehensive Cancer Center, Ann Arbor; Gordan Srkalovic, Sparrow Regional Cancer Center, Lansing; Sheela Tejwani, Henry Ford Hospital, Detroit, MI; William E. Barlow and Danika L. Lew, SWOG Statistical Center; Julie R. Gralow, Seattle Cancer Care Alliance, Seattle, WA; Gabriel N. Hortobagyi, University of Texas MD Anderson Cancer Center, Houston, TX; Eric P. Winer, Dana-Farber Cancer Institute, Boston, MA; Brian Leyland-Jones, Avera Cancer Institute, Sioux Falls, SD; Mark A. O'Rourke, Greenville Health System Cancer Institute/Greenville Community Clinical Oncology Program, Greenville, SC; Gerald V. Doyle, Immunicon, Huntingdon Valley, PA; and Robert B. Livingston, University of Arizona Cancer Center, Tucson, AZ.
Daniel F HayesJeffrey B. Smerage, Anne F. Schott, and Daniel F. Hayes, University of Michigan Comprehensive Cancer Center, Ann Arbor; Gordan Srkalovic, Sparrow Regional Cancer Center, Lansing; Sheela Tejwani, Henry Ford Hospital, Detroit, MI; William E. Barlow and Danika L. Lew, SWOG Statistical Center; Julie R. Gralow, Seattle Cancer Care Alliance, Seattle, WA; Gabriel N. Hortobagyi, University of Texas MD Anderson Cancer Center, Houston, TX; Eric P. Winer, Dana-Farber Cancer Institute, Boston, MA; Brian Leyland-Jones, Avera Cancer Institute, Sioux Falls, SD; Mark A. O'Rourke, Greenville Health System Cancer Institute/Greenville Community Clinical Oncology Program, Greenville, SC; Gerald V. Doyle, Immunicon, Huntingdon Valley, PA; and Robert B. Livingston, University of Arizona Cancer Center, Tucson, AZ. hayesdf@umich.edu.

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8M
Member Site CoreU10CA180821 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI Evanthia Galanis · 2014 to 2026
$177.3M
CANCER AND LEUKEMIA GROUP B MINORITY SATELLITE SUPPLEMENU10CA031946 · NCI · UNIVERSITY OF CHICAGO · PI BERTAGNOLLI, MONICA M · 1985 to 2013
$158.4M
SWOG Network Group Operations Center of the NCTNU10CA180888 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI PRIMO N. LARA · 2014 to 2026
$152.1M
SWOG - Foreign Accrual under UMiU10CA032102 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI BLANKE, CHARLES D. · 1985 to 2013
$141.3M
ECOG OPERATIONS OFFICE (IBCSG)U10CA021115 · NCI · UNIVERSITY OF WISCONSIN MADISON · PI COMIS, ROBERT L · 1985 to 2013
$132.6M
SWOG Statistics & Data Management Center complex - extension supplement for GY06U10CA180819 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Catherine M. Tangen · 2014 to 2026
$115.2M
SOUTHWEST ONCOLOGY GROUP--STATISTICAL CENTERU10CA038926 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI LEBLANC, MICHAEL L. · 1985 to 2013
$69.8M
SOUTHEAST CANCER CONTROL COSORTIUM, INCU10CA045808 · NCI · SOUTHEAST CLINICAL ONCOL RES CONSORTIUM · PI ATKINS, JAMES NORMAN · 1987 to 2013
$26.6M
COMMUNITY CLINICAL ONCOLOGY PROGRAMU10CA035431 · NCI · VIA CHRISTI REGIONAL MEDICAL CENTER · PI DAKHIL, SHAKER R · 1985 to 2014
$24.0M
MICHIGAN CANCER RESEARCH CONSORTIUM CCOPU10CA063848 · NCI · SAINT JOSEPH MERCY HEALTH SYSTEM · PI STELLA, PHILIP J · 1994 to 2014
$17.2M
GRAND RAPIDS CLINICAL ONCOLOGY PROGRAMU10CA035178 · NCI · SPECTRUM HEALTH HOSPITALS · PI PADULA, GILBERT DARIN ANTHONY · 1985 to 2014
$16.2M
NCI NIH HHS N01 CA004919NCI NIH HHS N01 CA027057NCI NIH HHS N01 CA032102NCI NIH HHS N01 CA035178NCI NIH HHS N01 CA035431NCI NIH HHS N01 CA038926NCI NIH HHS N01 CA045560NCI NIH HHS N01 CA045807NCI NIH HHS N01 CA046441NCI NIH HHS N01 CA063844NCI NIH HHS N01 CA067575NCI NIH HHS P30 CA016672NCI NIH HHS U10 CA004919NCI NIH HHS U10 CA012644NCI NIH HHS U10 CA014028NCI NIH HHS U10 CA016385NCI NIH HHS U10 CA020319NCI NIH HHS U10 CA021115NCI NIH HHS U10 CA022433NCI NIH HHS U10 CA027057NCI NIH HHS U10 CA031946NCI NIH HHS U10 CA032102NCI NIH HHS U10 CA035103NCI NIH HHS U10 CA035178NCI NIH HHS U10 CA035192NCI NIH HHS U10 CA035281NCI NIH HHS U10 CA035431NCI NIH HHS U10 CA037981NCI NIH HHS U10 CA038926NCI NIH HHS U10 CA042777NCI NIH HHS U10 CA045377NCI NIH HHS U10 CA045560NCI NIH HHS U10 CA045807NCI NIH HHS U10 CA045808NCI NIH HHS U10 CA046113NCI NIH HHS U10 CA046368NCI NIH HHS U10 CA046441NCI NIH HHS U10 CA058416NCI NIH HHS U10 CA058861NCI NIH HHS U10 CA058882NCI NIH HHS U10 CA063844NCI NIH HHS U10 CA063848NCI NIH HHS U10 CA067575NCI NIH HHS U10 CA067663NCI NIH HHS U10 CA073590NCI NIH HHS U10 CA074647NCI NIH HHS U10 CA076447NCI NIH HHS U10 CA086780NCI NIH HHS U10 CA095860NCI NIH HHS U10 CA105409NCI NIH HHS U10 CA180819NCI NIH HHS U10 CA180821NCI NIH HHS U10 CA180888
6 · The paper itself

Abstract

purposeIncreased circulating tumor cells (CTCs; five or more CTCs per 7.5 mL of whole blood) are associated with poor prognosis in metastatic breast cancer (MBC). A randomized trial of patients with persistent increase in CTCs tested whether changing chemotherapy after one cycle of first-line chemotherapy would improve the primary outcome of overall survival (OS). PATIENTS AND

methodsPatients with MBC who did not have increased CTCs at baseline remained on initial therapy until progression (arm A). Patients with initially increased CTCs that decreased after 21 days of therapy remained on initial therapy (arm B). Patients with persistently increased CTCs after 21 days of therapy were randomly assigned to continue initial therapy (arm C1) or change to an alternative chemotherapy (arm C2).

resultsOf 595 eligible and evaluable patients, 276 (46%) did not have increased CTCs (arm A). Of those with initially increased CTCs, 31 (10%) were not retested, 165 were assigned to arm B, and 123 were randomly assigned to arm C1 or C2. No difference in median OS was observed between arm C1 and C2 (10.7 and 12.5 months, respectively; P = .98). CTCs were strongly prognostic. Median OS for arms A, B, and C (C1 and C2 combined) were 35 months, 23 months, and 13 months, respectively (P < .001).

conclusionThis study confirms the prognostic significance of CTCs in patients with MBC receiving first-line chemotherapy. For patients with persistently increased CTCs after 21 days of first-line chemotherapy, early switching to an alternate cytotoxic therapy was not effective in prolonging OS. For this population, there is a need for more effective treatment than standard chemotherapy.

Indexed as

Drug SubstitutionAgedAntineoplastic AgentsBreast NeoplasmsDisease ProgressionFemaleHumansMiddle AgedNeoplastic Cells, CirculatingPrognosisProspective StudiesSurvival RateTreatment FailureAntineoplastic Agents

Identifiers

PMID24888818
PMCPMC4209100

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.